- Home
- HRTX vs ZNTL Comparison
HRTX vs ZNTL Comparison
Compare HRTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | ZNTL |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 156.7M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HRTX | ZNTL |
|---|---|---|
| Price | $0.79 | $2.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.50 | ★ $6.60 |
| AVG Volume (30 Days) | ★ 2.1M | 597.1K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $67,425,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.75 | $1.01 |
| 52 Week High | $2.61 | $3.95 |
Technical Indicators
Market Signals| Indicator | HRTX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 52.45 |
| Support Level | N/A | $1.29 |
| Resistance Level | $1.41 | $2.69 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.81 | 44.17 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.